Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular Targeting and Angiogenesis Modulation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EMCN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EMCN ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed for native mucin-type O-glycosylation. |
View EMCN Products |
| Gene Delivery | EMCN Lentivirus Premade Particles Full-length ORF for stable endothelial cell line construction. Titer >1x10^8 TU/ml. |
View EMCN Products |
| Benchmark Ab | Anti-EMCN Neutralizing Antibody (Clone EM-02) Recombinant positive control for adhesion blocking assays. |
View EMCN Products |
| Validator | EMCN siRNA Set For knockdown verification in HUVEC models. |
View EMCN Products |
| Related Target A | CD34 Endothelial progenitor marker, co-expressed with EMCN in vascular niches. |
View CD34 Products |
| Related Target B | SELE (E-Selectin) Adhesion molecule for leukocyte-endothelial interactions, functional antagonist to EMCN anti-adhesive function. |
View SELE Products |
| Related Target C | CD93 (Complement Component C1q Receptor) Endothelial surface receptor, synergistic targeting for vascular normalization. |
View CD93 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mucin Domain Glycosylation Fidelity | HEK293 Expression System ensuring native O-glycosylation patterns critical for anti-adhesive function validation |
| Cross-species Cyno/Mouse Preclinical Evaluation | Human/Mouse/Cyno EMCN ortholog proteins available with >95% purity, sequence verified by mass spectrometry |
| Endothelial Cell Model Construction | High-titer Lentivirus particles (>1x10^8 TU/ml) for stable EMCN overexpression in HUVECs, preserving native conformation |
| Adhesion vs. Anti-adhesion Mechanism | ECD-Fc fusion preserves extracellular domain flexibility and glycosylation status for biomolecular interaction assays |
| Sialomucin Family Off-Target Counter-Screening | Homolog panel proteins (CD34, Podocalyxin) strictly verified by mass spec for selectivity testing |
Live EMCN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EMCN therapeutics is intensifying, with major players shifting focus from traditional VEGF inhibitors to endothelial-specific targeting strategies. EMCN (Endomucin) is a transmembrane mucin-like glycoprotein highly expressed on microvascular endothelial cells and hematopoietic progenitors. The current pipeline is predominantly early-stage, with antibody-drug conjugates (ADCs) and monoclonal antibodies leading exploration in solid tumor vascular targeting and multiple myeloma. As first-generation anti-angiogenic therapies face resistance, targeting EMCN offers an alternative strategy to modulate VEGFR2 internalization and vascular remodeling. High-purity, natively glycosylated antigens are essential for screening highly specific antibodies and novel nanotherapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotech, Academic Labs | Solid Tumors (Vascular Targeting) | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Monoclonal Antibody | Preclinical Programs | Inflammation, Ischemia, Solid Tumors | Epitope Mapping & Adhesion Blocking Assay (Need natively glycosylated antigen and functional endothelial cell model) |
| Bispecific / Fusion Protein | Translational Researchers | Refractory Tumors, Angiogenesis Resistance | Heterodimer Validation & Dual-target SPR (Need conformationally intact antigens and VEGFR2/EMCN panels) |
| CAR-T/NK | Cell Therapy Innovators | Vascular Diseases | Cell Surface Expression Validation (Need Lentivirus stable lines) |
This document is derived from merged input candidates with deduplication.